THE ASSESSMENT OF THE IMPACT OF VITAMIN D ON THE INTENSITY OF LOWER URINARY TRACT SYMPTOMS AND THE QUALITY OF LIFE OF PERSONS WITH BENIGN PROSTATIC HYPERPLASIA
Abstract
Introduction/Aaim: Older men with benign prostatic hyperplasia (BPH) are more likely to have a poor quality of life. The aim of this study was to examine the influence of serum vitamin D on the intensity of lower urinary tract symptoms and the quality of life of persons with benign prostatic hyperplasia.
Methods: The study was conducted as a cross-sectional study. The study included 117 persons with benign prostatic hyperplasia (BPH) treated at the Clinical Center of Montenegro in Podgorica from May 10th, 2022 to August 15th, 2022. Data were collected with the help of the general questionnaire from electronic medical records, as well as with the International Prostate Symptom Score (IPSS) questionnaire. Spearman’s correlation coefficient was used for the statistical analysis of data.
Results: The average age of participants was 62.97±11,57. The average value of the intensity of symptoms in patients with BPH according to the IPSS questionnaire was 8.54. Of the 117 participants with BPH, 57 (48.7%) had moderate symptoms, 56 (47.9%) mild, and 4 (3.4%) severe. A significant negative correlation (r=-0.316; p=0.010) was obtained between vitamin D levels and average values of symptoms according to the IPSS questionnaire. Also, a significant negative correlation was obtained between serum vitamin D values and all individually assessed values of BPH symptoms according to the IPSS questionnaire (sensation of incomplete emptying of the bladder during urination – p=0.040; repeated urination within two hours from the previous urination – p<0.001; intermittent urination – p=0.005; inability to postpone urination – p=0.036; a thin and weak urinary stream – p=0.001; straining to begin urinating with the sensation of the need to urinate – p=0.046 and nocturia – p=0.011). Based on the serum level of vitamin D, the participants had optimal levels of vitamin D in 52.1% of cases, insufficient levels in 29.1% of cases and deficit in 18,8%. An inverse relationship between the average values of serum vitamin D and quality of life according to ISPP questionnaire was observed, but this relationship was not significant (r =-0.365; p=0.160).
Conclusion: The results of the study show that higher levels of vitamin D lead to the significant reduction in urological symptoms in patients with BPH, which points to the need to prevent vitamin D deficiency. Further research in this field is necessary aimed at making more detailed recommendations.
References
1. Lee SU, Lee SH, So AH, Park JI, Lee S, Oh IH, et al. Association between benign prostatic hyperplasia and suicide in South Korea: A nationwide retrospective cohort study. PLoS One. 2022;17(3):e0265060. doi: doi: 10.1371/ journal.pone.0265060. eCollection 2022.
2. Sarma AV, Wei JT. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. N Engl J Med. 2012;367(3):248- 57. doi: 10.1056/NEJMcp1106637.
3. Langan RC. Benign Prostatic Hyperplasia. Prim Care Clin Off Pract. 2019;46(2):223-32. doi: 10.1016/j. pop.2019.02.003.
4. Kim EH, Larson JA, Andriole GL. Management of Benign Prostatic Hyperplasia. Annu Rev Med. 2016;67(1):137-51. doi: 10.1146/annurev-med-063014-123902.
5. Park S, Lee KS, Choi M, Lee M. Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009–2016. Medicine (Baltimore). 2022;101(36):e30091. doi: 10.1097/MD.0000000000030091.
6. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms. Urol Clin North Am. 2016;43(3):289–97. doi: 10.1016/j.ucl.2016.04.001
7. Liu ZM, Wong C, Chan D, Woo J, Chen YM, Chen B, et al. Association of Circulating 25(OH)D and Lower Urinary Tract Symptoms: A Four-Year Prospective Study among Elderly Chinese Men. Nutrients. 2016;8(5):273. doi: 10.3390/nu8050273.
8. Chen Y, Xu H, Liu C, Gu M, Chen Q, Zhan M, et al. Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence. Dis Markers. 2021;2021:4029470. doi: 10.1155/2021/4029470
9. Barry MJ, Fowler FJ Jr, Bin L, Pitts JC 3rd, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 1997;157(1):10-4; discussion 14-5.
10. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637-49. doi: 10.1016/j. eururo.2003.08.015.
11. Kuliš T, Gašparić M, Prižmić M, Kovačić D, Kolumbić Lakoš A, Kaštelan Ž. Simptomi i kvaliteta života u bolesnika s BPH. Medicus. 2015;25(1):87-92.
12. Ilić A, Denović D. Kliničko morfološke karakteristike patoloških promjena u prostati. Praxis Medika. 2019;48(1):1-8. doi: 10.5937/pramed1901001I
13. Tóth Z, Szalay B, Gyarmati B, Jalal DA, Vásárhelyi B, Szabó T. Vitamin D Deficiency has no Impact on PSA Reference Ranges in a General University Hospital - A Retrospective Analysis. EJIFCC. 2020;31(3):225-230.
14. Grammatikopoulou MG, Gkiouras K, Papageorgiou SΤ, Myrogiannis I, Mykoniatis I, Papamitsou T, et al. Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials. Nutrients. 2020;12(10):2985. doi: 10.3390/nu12102985.
15. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;167(8):925-34. doi: 10.1093/aje/kwm389.
16. Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115(4):508-19. doi: 10.1111/bju.12745.